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The association of immunodeficiency and autoimmunity may 
 represent a paradox, yet it has been described in an increasing num-
ber of conditions. Use of unbiased genomic approach to identify 
novel forms of primary immunodeficiencies (PIDs), along with in-
depth functional studies in biological samples from affected indi-
viduals continue to unravel novel mechanisms underlying immune 
dysregulation in patients with altered ability of fighting pathogens. 
In particular, it has been clearly established that genetic defects that 
affect T and B cell development compromise not just the ability 
to generate a diversified repertoire of lymphocytes capable of rec-
ognizing multiple pathogens, but also impinge on mechanisms of 
central and peripheral tolerance, hence favoring autoimmune and 
inflammatory manifestations.
Yet, the diagnosis of autoimmune symptoms in the context of 
PIDs is troublesome, the prognosis unclear, and the treatment chal-
lenging. In the present collection of manuscripts, several experts 
in the field provide an overview of the spectrum of different forms 
of monogenic defects of the immune system manifesting also with 
autoimmunity, and discuss established and novel mechanisms 
involved in immune dysregulation.
Studies on patients with Immunedysregulation-Polyendo-
crinopathy-Enteropathy-X-linked (IPEX) Syndrome, have paved 
the way to understand the phenotype arising from impaired 
peripheral tolerance due to dysfunctional regulatory T cells 
(Treg) expressing mutated FOXP3. However, this important T 
cell subpopulation can also be affected in other forms of PID, 
such as Wiskott–Aldrich syndrome (WAS) and adenosine deami-
nase (ADA) deficiency. In these disorders, the underlying genetic 
defect affects multiple cell types, resulting in impaired immune 
defense, but also poor Treg function. Similarly, STAT5B muta-
tions disrupt an essential intracellular transcriptional activa-
tor for Treg cells, causing reduction of Treg number in affected 
individuals.
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystro-
phy (APECED) is an autosomal recessive condition due to mutation 
of the Autoimmune regulator (AIRE) gene. Patients with APECED 
present with predominant organ specific  autoimmunity and autoanti-
bodies with multiple specificities. AIRE has been shown to play a criti-
cal role in allowing expression of self-antigens in the thymus, thereby 
permitting deletion of self-reactive T lymphocytes or their diversion 
to Treg cells. Thus APECED stands as the prototypic monogenic dis-
order of central T cell tolerance. While it is still questionable whether 
deficiency of AIRE also affects peripheral tolerance, recent data indicate 
that the autoimmune-associated tissue damage may not be primarily 
due to autoantibodies, but rather to autoreactive CD8+ T cells.
Moreover, recent studies in patients affected with Common 
Variable Immunodeficiency, a condition in which proper specific 
antibody production is deficient in favor of pathogenic autoanti-
body secretion, have highlighted the importance of mechanisms 
that control B cell development and receptor editing in maintaining 
immune homeostasis.
Finally, two manuscripts call the attention to the dual role of cer-
tain cell types and their ability to acquire different immunological 
functions depending on the environment in which they differenti-
ate, as described for Th17 cells and dendritic cells, at the end of the 
Topic. Possibly, the future of medicine should aim to implement 
physiological plasticity and to empower epigenetics modifications 
in order to recover from inborn errors of Nature.
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